When does management of Crohn disease warrant assessment of C-reactive protein and fecal calprotectin and when is endoscopy indicated? Test your IBD IQ.
New clinical practice guidelines from the American Gastroenterological Association (AGA) advise on use of biomarkers in the management of Crohn disease (CD).
Although managing CD has traditionally relied on endoscopy assessment of disease activity and mucosal healing, the AGA recognizes that reliance on endoscopy is limited by cost and resources as well as the test's invasiveness and patient acceptance. The guideline addresses these limitations by advising when biomarkers can serve as surrogates of endoscopic assessment.
The quiz above tests your familiarity with the role of the biomarkers C-reactive protein (CRP) and fecal calprotectin in the management of CD, as characterized in the AGA guideline. For a quick review, click here for the Patient Care Guideline Topline on the use of biomarkers in management of Crohn disease, based on the AGA recommendations.